Vinaya Simha

Vinaya Simha

Auto-generated profile, based on publicly available information

Vinaya Simha

Division of Endocrinology, Mayo Clinic , Rochester, MN 55905

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2020 in BMJ
Verified
Journal Article
Closed access
PDF file
VSVinaya Simha
Vinaya Simha
Hypertriglyceridemia is one of the most common lipid abnormalities encountered in clinical practice. Many monogenic disorders causing severe hypertriglyceridemia have been identified, but in most patients triglyceride elevations result from a combination of multiple genetic variations with small effects and environmental factors. Common secondary causes include obesity, uncontrolled diabetes, alcohol misuse, and various commonly used drugs. Correcting these factors and optimizing lifestyle choices, including dietary modification, is important before starting drug treatment. The goal of drug treatment is to reduce the risk of pancreatitis in patients with severe hypertriglyceridemia and cardiovascular disease in those with moderate hypertriglyceridemia. This review discusses the various genetic and acquired causes of hypertriglyceridemia, as well as current management strategies. Evidence supporting the different drug and non-drug approaches to treating hypertriglyceridemia is examined, and an easy to adopt step-by-step management strategy is presented.

1 December 2020 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
CHCarina P. Himes
Carina P. Himes
RGRavindra Ganesh
Ravindra Ganesh
EWElizabeth C. Wight
Elizabeth C. Wight
VSVinaya Simha
Vinaya Simha
MLMark Liebow
Mark Liebow

18 February 2016 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
PDF file
PMPatrick M. Moriarty
Patrick M. Moriarty
KPKlaus G. Parhofer
Klaus G. Parhofer
SBStephan P. Babirak
Stephan P. Babirak
EDEmil Degoma
Emil Degoma
PDP. Barton Duell
P. Barton Duell
GMGaren Manvelian
Garen Manvelian

17 February 2023 in JCEM Case Reports
Verified
Journal Article
Open access
PDF file
Maheswaran DhanasekaranMaheswaran Dhanasekaran
Maheswaran Dhanasekaran
RSRashi Sandooja
Rashi Sandooja
AHAlexandra S Higgins
Alexandra S Higgins
VSVinaya Simha
Vinaya Simha
Immune checkpoint inhibitors (ICIs) targeting cancer cells that evade immune T-cell regulation have revolutionized the treatment of metastatic carcinomas. Unfortunately, secondary endocrinopathies associated with ICI, including adrenal insufficiency, primary hypothyroidism, autoimmune diabetes, and rarely hypoparathyroidism, are increasing. Lipodystrophy, presumably due to the autoimmune destruction of adipocytes, leading to metabolic complications, is a less recognized adverse effect of ICI therapy. We present a case of a 66-year-old Caucasian woman treated with pembrolizumab, an anti-programmed death 1 inhibitor, for metastatic lung adenocarcinoma. Fifteen months after the treatment initiation, she was found to have hyperglycemia, hyperlipidemia, and hepatic steatosis but without any evidence of autoimmune diabetes. She was also noted to have isolated buccal fat pad loss, raising suspicion of acquired lipodystrophy. Despite well-preserved subcutaneous fat over the trunk and limbs, she had undetectable serum leptin levels. Whole-body fluorodeoxyglucose (FDG)-positron emission tomography scan showed diffuse mild FDG activity throughout the subcutaneous tissue, suggesting underlying inflammation. Over the next 3 months, she developed progressive fat loss leading to generalized lipodystrophy. Adipose tissue dysfunction, secondary to ICI-induced subclinical panniculitis, precedes overt fat loss and is characterized by hypoleptinemia and metabolic abnormalities.

19 February 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
RBRebecca J. Brown
Rebecca J. Brown
BABaris Akinci
Baris Akinci
MYMatheos Yosef
Matheos Yosef
HPHelen Phillips
Helen Phillips
SKShokoufeh Khalatbari
Shokoufeh Khalatbari
EOElif A Oral
Elif A Oral
Context: Lipodystrophy syndromes are rare disorders characterized by deficient adipose tissue, leading to insulin resistance, dyslipidemia, and organ system abnormalities. Objective: Our goal was to develop a lipodystrophy severity score (LDS) to holistically capture the diverse manifestations of lipodystrophy into a numerical score to aid in prediction of clinical outcomes and/or treatment impact. Design: An 8-domain LDS was developed by 8 disease experts in consultation with patient organizations. The LDS was rated for feasibility and content validity by 28 additional clinicians and 9 patient representatives. LDS was compared to the Clinical Global Impression (CGI) of severity for 20 putative patient profiles, each at 2 different time points, and by comparing change in LDS to global impression of change. For external validation, LDS was calculated in 2 cohorts of patients with lipodystrophy treated with metreleptin. Results: LDS domains include Diabetes/Insulin Resistance, Microvascular Complications of Diabetes, Lipids, Cardiovascular, Liver, Kidney, Reproductive, and Other. Each domain is assessed by 1 or more questions assessing both lifetime and recent complications of lipodystrophy. The LDS had high content validity and feasibility and high reliability by intraclass correlation coefficients (>0.95). Global and domain-specific LDS were strongly correlated with CGI, as were changes in scores across visits (R = 0.79-0.99, P < .001 for all). In generalized lipodystrophy, metreleptin significantly reduced LDS (from 46 to 26 at 12 months, P < .001). The reductions were smaller in partial lipodystrophy (from 65 to 61 at 12 months, P = .04). Conclusion: The LDS can reflect the severity of diverse manifestations of lipodystrophy and monitor changes following interventions.

6 October 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
VSVinaya Simha
Vinaya Simha
ILIan R Lanza
Ian R Lanza
SDSurendra Dasari
Surendra Dasari
KKKatherine A Klaus
Katherine A Klaus
NBNathan Le Brasseur
Nathan Le Brasseur
KNK Sreekumaran Nair
K Sreekumaran Nair
Context: Familial partial lipodystrophy (FPL), Dunnigan variety is characterized by skeletal muscle hypertrophy and insulin resistance besides fat loss from the extremities. The cause for the muscle hypertrophy and its functional consequences is not known. Objective: To compare muscle strength and endurance, besides muscle protein synthesis rate between subjects with FPL and matched controls (n = 6 in each group). In addition, we studied skeletal muscle mitochondrial function and gene expression pattern to help understand the mechanisms for the observed differences. Methods: Body composition by dual-energy X-ray absorptiometry, insulin sensitivity by minimal modelling, assessment of peak muscle strength and fatigue, skeletal muscle biopsy and calculation of muscle protein synthesis rate, mitochondrial respirometry, skeletal muscle transcriptome, proteome, and gene set enrichment analysis. Results: Despite increased muscularity, FPL subjects did not demonstrate increased muscle strength but had earlier fatigue on chest press exercise. Decreased mitochondrial state 3 respiration in the presence of fatty acid substrate was noted, concurrent to elevated muscle lactate and decreased long-chain acylcarnitine. Based on gene transcriptome, there was significant downregulation of many critical metabolic pathways involved in mitochondrial biogenesis and function. Moreover, the overall pattern of gene expression was indicative of accelerated aging in FPL subjects. A lower muscle protein synthesis and downregulation of gene transcripts involved in muscle protein catabolism was observed. Conclusion: Increased muscularity in FPL is not due to increased muscle protein synthesis and is likely due to reduced muscle protein degradation. Impaired mitochondrial function and altered gene expression likely explain the metabolic abnormalities and skeletal muscle dysfunction in FPL subjects.